Table 4. Comparison of KIRs and KIR ligands between controls and patients with Colorectal Cancer.
Only the activating and inhibitory KIRs and ligands found to be associated with recurrence are included into the analysis.
| Control | Colorectal Cancer | ||
|---|---|---|---|
| (n:154) | (n:87) | P | |
| 2DS1 | 75/154 (48.7%) | 40/87 (45.97%) | 0,68 |
| 2DS2 | 103/154 (66.88%) | 54/87 (62.07%) | 0,45 |
| 2DS3 | 52/154 (33.76%) | 34/87 (39.08%) | 0,41 |
| (2DS1+2DS2+2DS3) | 23/154 (14.93%) | 16/87 (18.39%) | 0,26 |
| (2DS1+2DS2+3DS1) | 43/154 (27.92%) | 20/87 (22.98%) | 0,40 |
| (2DS1+2DS2+2DS3+3DS1) | 20/154 (12.98%) | 12/87 (13.79%) | 0.86 |
| (2DS1+2DS2) | 54/154 (35.06%) | 28/87 (32.18%) | 0,65 |
| (2DS1+2DS3) | 25/154 (16.23%) | 16/87 (18.39%) | 0,67 |
| (2DS2+2DS3) | 49/154 (31.82%) | 30/87 (34.48%) | 0,67 |
| 3DS1 | 76/154 (49.35%) | 35/87 (40.22%) | 0,17 |
| 2DL1 | 147/154 (95.45%) | 77/87 (88.5%) | 0,04 |
| 2DL2 | 103/154 (66.88%) | 68/87 (78.16%) | 0,001 |
| 2DL2-groupC1 | 64/111 (57.65%) | 64/87 (73.56%) | 0,02 |
| 2DL1-groupC2 | 78/111 (70.27%) | 71/87 (81.61%) | 0,067 |
| 2DS2-GroupC1 | 63/111 (56.76%) | 52/87 (59.77%) | 0,67 |
| A-Bw4 | 63/136 (46.32%) | 58/87 (66.6%) | 0,003 |